Table 1 Baseline patient characteristics. Medical and demographic data. Data are presented as mean ± standard deviation (SD) or number

143

(100%)

 HF with reduced EF (< 40%)

106

(74.1%)

 HF with preserved EF (> 40%)

37

(25.9%)

 Total

m 119: f 24

(83.2%: 16.8%)

 HFrEF^b

m 91: f 15

(63.6%: 10.5%)

 HFpEF^c

m 28: f 9

(19.5%: 6.29%)

 HFrEF^b

  Ischemic cardiomyopathy

48

(33.6%)

  Dilated cardiomyopathy

36

(25.2%)

  Pulmonary hypertension and right ventricular dysfunction

2

(1.40%)

  Hypertensive heart disease

1

(0.70%)

  Congenital heart defect

1

(0.70%)

  Not specified

18

(12.6%)

 HFpEF^c

  Ischemic cardiomyopathy

7

(4.90%)

  Dilated cardiomyopathy

8

(5.59%)

  Pulmonary hypertension and right ventricular dysfunction

6

(4.20%)

  Pericarditis constrictiva

2

(1.40%)

  Hypertensive heart disease

1

(0.70%)

  Congenital heart defect

1

(0.70%)

  Not specified

12

(8.39%)

 HFrEF^b

  Tricuspid regurgitation I°

11

(7.69%)

  II°

22

(15.4%)

  III°

9

(6.29%)

  Mitral regurgitation I°

14

(9.79%)

  II°

27

(18.9%)

  III°

8

(5.59%)

 HFpEF^c

  Tricuspid regurgitation I°

1

(0.70%)

  II°

5

(3.50%)

  III°

7

(4.90%)

  Mitral regurgitation I°

3

(2.10%)

  II°

5

(3.50%)

  III°

2

(1.40%)

  HFrEF ^b

   Angiotensin Converting Enzyme Inhibitors / Angiotensin Receptor Blockers

58

(40.6%)

   Beta Blockers

69

(48.3%)

  Spironolacton

40

(28.0%)

  Angiotensin Converting Enzyme Inhibitors / Angiotensin Receptor Blockers

20

(14.0%)

  Beta Blockers

21

(14.7%)

  Spironolacton

13

(9.09%)

  Erythropoietin

8

(5.59%)

  APD^e

36

(25.2%)

  CAPD^f

54

(37.8%)

  IPD^g

3

(2.10%)

  APD^e

14

(9.79%)

  CAPD^f

18

(12.6%)

  IPD^g

1

(0.70%)

 HFrEF^b

11

(7.69%)

 HFpEF^c

5

(3.50%)